Crucially, TIM3 blockade retarded HSC activation and fibrosis during NASH development, as indicated by Sirius red staining and fibrosis-related biomarkers (Fig. 6D, E, S8E). The gene discussed is HAVCR2; the disease is metabolic dysfunction-associated steatohepatitis.